Serum galectin-3 and TGF-beta levels in patients with sarcoidosis

Kobak, Şenol; Akyıldız, Muhittin; Gökduman, Ayşe; Atabay, Tennur; Vural, Hüseyín

doi:10.1016/j.reuma.2020.08.007

Cited by 5 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study showed that HIF1A protein and mRNA levels were decreased in sarcoidosis granulomas 30 . We and others have found alterations in TGFB1, which encodes TGF-β, in pulmonary sarcoidosis 31,32 . Additionally, TGF-β genotypes have been associated with sarcoidosis severity 31 .…”

Section: Discussionmentioning

confidence: 70%

Multi-Omic Signatures of Sarcoidosis and Progression in Bronchoalveolar Lavage Cells

Konigsberg

Lin

Liao

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction: Sarcoidosis is a heterogeneous, granulomatous disease that can prove difficult to diagnose, with no accurate biomarkers of disease progression. Therefore, we profiled and integrated the DNA methylome, mRNAs, and microRNAs to identify molecular changes associated with sarcoidosis and disease progression that might illuminate underlying mechanisms of disease and potential genomic biomarkers. Methods: Bronchoalveolar lavage cells from 64 sarcoidosis subjects and 16 healthy controls were used. DNA methylation was profiled on Illumina HumanMethylationEPIC arrays, mRNA by RNA-sequencing, and miRNAs by small RNA-sequencing. Linear models were fit to test for effect of diagnosis and phenotype, adjusting for age, sex, and smoking. We built a supervised multi-omics model using a subset of features from each dataset. Results: We identified 46,812 CpGs, 1,842 mRNAs, and 5 miRNAs associated with sarcoidosis versus controls and 1 mRNA, SEPP1 - a protein that supplies selenium to cells, associated with disease progression. Our integrated model emphasized the prominence of the PI3K/AKT1 pathway in sarcoidosis, which is important in T cell and mTOR function. Novel immune related genes and miRNAs including LYST, RGS14, SLFN12L, and hsa-miR-199b-5p, distinguished sarcoidosis from controls. Our integrated model also demonstrated differential expression/methylation of IL20RB, ABCC11, SFSWAP, AGBL4, miR-146a-3p, and miR-378b between non-progressive and progressive sarcoidosis. Conclusions: Leveraging the DNA methylome, transcriptome, and miRNA-sequencing in sarcoidosis BAL cells, we detected widespread molecular changes associated with disease, many which are involved in immune response. These molecules may serve as diagnostic/prognostic biomarkers and/or drug targets, although future testing will be required for confirmation.

show abstract

Section: Discussionmentioning

confidence: 70%

Multi-Omic Signatures of Sarcoidosis and Progression in Bronchoalveolar Lavage Cells

Konigsberg

Lin

Liao

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…A previous study reported that galectin-3 levels were elevated in sarcoidosis patients with cardiac involvement when compared to the controls [18]. Another study reported that serum galectin-3 levels were similar in sarcoidosis patients and control groups [19]. These data indicate that galectin-3 may result in fibrosis in several organs.…”

Section: Discussionmentioning

confidence: 80%

The Role of Serum Galectin-3 Levels in Patients with Sarcoidosis

et al. 2021

View full text Add to dashboard Cite

introduction: Galectin-3 is a multi-functional protein and previous studies have suggested that levels of serum galectin-3 increase in the presence of diseases that progress with pulmonary fibrosis. Therefore, the role of galectin-3 levels in the staging and assessing of the severity of sarcoidosis is investigated in the present study. Methods and Subjects: The present study was conducted on a total of 73 subjects, including 25 healthy individuals and 48 patients with a pathologically confirmed diagnosis of sarcoidosis in which other potential causes had been ruled out. Galectin-3 levels of all subjects were measured and compared in terms of such parameters as hemogram, biochemistry, age, body mass index and smoking status. Intervention: In our study, no intervention was made to the patients. Main Outcome Measures: The mean galectin-3 levels of the sarcoidosis patients (14.87±5.57) were significantly higher than those measured in the healthy subjects (11.81± 2.67), and themean galectin-3 levels differed significantly among those at different stages of the disease (p<0.05). In particular, the average level of galectin-3 sarcoidosis patients had grade 2 and above significantly higher. Results: In addition, serum galectin-3 levels in the sarcoidosis patients had significant positive correlations with blood BUN, ALP, WBC, RBC, HGB and neutrophil levels (34.9% [p<0.05]; 40.1% [p<0.05]; 41.2% [p<0.01]; 43.3% [p<0.01]; 34.7% [p<0.05] and 40.6% [p<0.01], respectively),and a significant negative correlation with PDW levels (p<0.05). Conclusion: Serum galectin-3 levels are significantly elevated in sarcoidosis patients with parenchymal involvement at stages 2 or higher, suggesting that serum galectin-3 levels can be used to estimate disease severity in sarcoidosis.

show abstract